GeoVax Labs Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -2.75 M-11.2 M-19.03 M-25.17 M-24.68 M -24.27 M Mittelzufluss aus Investitionstätigkeit -156.79 K-47.72 K-134.26 K-48.95 K-20.65 K -27.61 K Zahlungsströme aus der Finanzierungstätigkeit 12.51 M12.78 M35.35 M4.06 M23.75 M 20.71 M Freier Cashflow -2.91 M-11.24 M-19.16 M-25.22 M-24.7 M -24.29 M

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.

GOVX

Financials

GeoVax Labs Inc

Nachrichten

D. Boral Capital stuft GeoVax Labs auf "Halten" herab: Kapitalengpässe und fehlende Impulse belasten

D. Boral Capital downgrades GeoVax Labs stock rating to Hold

Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Aclarion (NASDAQ:ACON), AXT (NASDAQ:AXTI)

Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results - Autozi Internet Tech (NASDAQ:AZI), Conagra Brands (NYSE:CAG)

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax meldet Umsatzrückgang in Q3 2025 – Aktie gibt nach/n

GeoVax auf der Emerging Growth Conference: Impfstoff-Hoffnung für Immungeschwächte/n

GeoVax at Emerging Growth Conference: Vaccine Promise for Immunocompromised

GeoVax Labs at H.C. Wainwright: Strategic Focus on Vaccine Innovation

GeoVax Labs at Emerging Growth Conference 85: Strategic Vaccine Developments

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?

GeoVax Labs receives Nasdaq notice for non-compliance with minimum bid price